BioVaxys Selected to Present its Universal Vaccine Platform for Individualized Cancer Therapy at the 2018 BIO Investor Forum

BioVaxys LLC (www.biovaxys.com), a clinical-stage immune-oncology company developing a universal vaccine platform for individualized cancer therapy, has been selected to present at the 17th Annual BIO Investor Forum, being held October 17-18, 2018, at the Westin St. Francis in San Francisco, CA.

Kenneth Kovan, one of the founders of BioVaxys, will discuss the companys strategy and its outlook for the future, including its recent patent filings and clinical development plans for its novel combination multihaptenized autologous cancer vaccine and checkpoint antibody immunotherapeutic approach.

Details of the presentation are as follows:

  • Date: Thursday, October 18, 2018
  • Time: 2:00 pm PDT
  • Location: Elizabethan A

Investors attending BIO Investor Forum who would like to meet with BioVaxys founders, scientific team and management should request a meeting through the BIO portal, or contact Kenneth Kovan at [email protected] or 610 977 2440.

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 

About The BIO Investor Forum

The BIO Investor Forum is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth watch list in 2019.

About BioVaxys LLC

BioVaxys LLC, a privately-held, clinical stage biotechnology company that is developing highly targeted, patient-specific, immunotherapeutic vaccines to treat various solid tumor types. The Companys lead clinical program is a bihaptenized autologous vaccine that will initially be developed and marketed for melanoma, ovarian cancer, and other solid tumors. Early stage internal drug discovery efforts are focused on identifying new cancer antigens which may lead to the development of novel next-generation cancer vaccines.

BioVaxys LLC
Kenneth Kovan, 610-977-2440
[email protected]

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 
Close
Stay Updated To Save Money & Time. Join Our Free Newsletter. 
. Indepth Analysis & Opinion       Interviews          . Exclusive Reports 
. Free Digital Magazines        . News & updates        . Event Invitations
& Much More Delivered To Your Inbox For Free. 
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.
 
Close